Screener
Iovance Biotherapeutics, Inc. IOVA Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept iova:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan.
The source filing: Iovance Biotherapeutics, Inc.’s 10-K, filed February 24, 2026. Open the filing →
- Filed
- Feb 24, 2026, 9:35 AM EST
- Fiscal year
- FY2025
- Accession
- 0001104659-26-018899
FAQ
- What is Iovance Biotherapeutics, Inc.'s proceeds from issuance of common stock under employee stock purchase plan?
- Iovance Biotherapeutics, Inc. (IOVA) reported proceeds from issuance of common stock under employee stock purchase plan of $839K in Q4 2025.
- How has Iovance Biotherapeutics, Inc.'s proceeds from issuance of common stock under employee stock purchase plan changed year-over-year?
- Iovance Biotherapeutics, Inc.'s proceeds from issuance of common stock under employee stock purchase plan decreased by 39.6% year-over-year, from $1.39M to $839K.
- What does proceeds from issuance of common stock under employee stock purchase plan mean?
- Measures the cash inflows generated from the sale of common stock to employees through designated purchase plans. This metric reflects the level of employee participation in equity ownership programs. It serves as a source of non-dilutive-like financing while aligning employee interests with shareholder value.
Ask your AI about Iovance Biotherapeutics, Inc.'s proceeds from issuance of common stock under employee stock purchase plan.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude